Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorPeking University People's Hospital
About this trial
Immune thrombocytopenia (ITP) is an acquired bleeding disorder mediated by immune-related platelet destruction and impaired platelet production. Immune thrombocytopenia may increase the risk of cerebral infarction and represents a relatively uncommon etiology of acute ischemic stroke. This disease is associated with high disability and mortality rates, poses significant therapeutic challenges, and constitutes a serious threat to human health. Therefore, research on the diagnosis, treatment, and prognosis of ITP combined with acute ischemic stroke is of great significance for improving patients' quality of life and survival outcomes. However, most current hematologic cohort studies are based on single-center or limited multicenter sample sizes, lacking comprehensive and large-scale prospective cohort studies. Our center plans to conduct a large-sample, combined retrospective and prospective longitudinal cohort study. This study will register patients' basic information and diagnosis, follow up with patients through questionnaires, telephone calls, video consultations, online platforms, and in-person visits to record treatment and comorbidity data, collect prognostic information, and retrieve hospitalization and outpatient costs through medical record systems. The study aims to provide comprehensive data on the incidence, treatment, prognosis, and healthcare costs of ITP patients with acute ischemic stroke in China.
Eligibility criteria
Qualifiers
Diagnosed with immune thrombocytopenia, and subsequently identified patients with acute ischemic stroke.
Since January 1, 2005, patients who received treatment at Peking University People's Hospital.
Disqualifiers
For any reason, such as the occurrence of severe mental disorders, the follow-up information may be unavailable;
Patients deemed unsuitable for the study by the researchers.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
500 Participants
are grouped into 3 trial groupsLocations
Sponsors and collaborators
Peking University People's Hospital
Lead sponsor
Jiangsu province hospital of TCM
Collaborator
Army Medical University, China
Collaborator
Henan Cancer Hospital
Collaborator
The Affiliated People's Hospital of Ningbo University
Collaborator
West China Hospital
Collaborator
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Collaborator
Zhejiang University
Collaborator
The Second Hospital Of Hebe Medical University
Collaborator
Kunming Medical University Second Affiliated Hospital
Collaborator
Shanghai Zhongshan Hospital
Collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
Huazhong Science & Technology Shanxi Baiqiu En Hospital
Collaborator
NORTHERN JIANGSU PEOPLE'S HOSPITAL 1900
Collaborator
Tongji Hospital
Collaborator
Xuzhou Medical University Affiliated Hospital of Huaian
Collaborator
Affiliated Hospital of Fujian Medical University, Xiehe Branch
Collaborator
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborator
First Affiliated Hospital of Guangxi Medical University
Collaborator
The Third Xiangya Hospital of Central South University
Collaborator
Second Xiangya Hospital of Central South University
Collaborator
Xiangya Hospital of Central South University
Collaborator
Qilu Hospital of Shandong University
Collaborator
Southern Medical University - Southern Hospital
Collaborator
The Second Hospital of Hebei Medical University
Collaborator
The First Affiliated Hospital of University of Science and Technology of China
Collaborator
The First Affiliated Hospital of Nanchang University
Collaborator
First Affiliated Hospital of Xinjiang Medical University
Collaborator
North China University of Science and Technology
Collaborator
Source ClinicalTrials.gov